Parkwalk News

2 January 2019

Cytora and QBE expand its relationship to enhance data-driven business insurance

By |January 2nd, 2019|

Following a successful pilot project, QBE has begun using Cytora’s Risk Engine technology to enhance underwriting decisions across its commercial portfolio.
The Cytora Risk Engine learns the patterns of good and bad risks over time, combining the digital footprint of every business with insurers’ internal data to generate a comprehensive risk profile and score for […]

12 December 2018

Istesso – Parkwalk investment

By |December 12th, 2018|

Parkwalk are delighted to welcome Istesso to its portfolio following an investment from the Parkwalk Opportunities EIS Fund.

Istesso is a drug development company working in the field of immunometabolism. It’s pre-clinical and clinical assets work by reprogramming cellular metabolism and have applications in autoimmune conditions. Istesso’s lead drug, MBS2320, is in a Phase 2a […]

MedaPhor – Parkwalk investment

By |December 11th, 2018|

We are delighted to announce that the Parkwalk Opportunities Fund has  participated in the recent financing round of Medaphor Group plc, the Cardiff University Spin-out and global provider of advanced ultrasound training simulators and ultrasound clinical support for medical professionals.

GOV.UK: Oxford Photovoltaics: a shining light in solar cell innovation

By |December 7th, 2018|

Oxford Photovoltaics: a shining light in solar cell innovation

Early support from Innovate UK kick-started Oxford University spin-out which has set a world record for converting sunlight into power.

Dr Chris Case and Professor Henry Snaith of Oxford Photovoltaics

An Oxfordshire company backed by early financial support from Innovate UK is developing next-generation solar cell technology for […]

Brainomix partners with Oxford University in UK Government funded £17.5 million AI Programme

By |December 7th, 2018|

Brainomix, an Oxford-based world leader in medical imaging software, is teaming up with the University of Oxford to become one of its technology providers for a £17.5m UK government funded project. Brainomix will demonstrate the significant health economic benefits of its AI-based proprietary imaging software solution, e-Stroke Suite, which is already used in routine clinical practice at […]

Ceres Power and Weichai finalise strategic collaboration and JV Agreement

By |December 4th, 2018|

Ceres Power (AIM: CWR, “Ceres”), a world-leading, low cost Solid Oxide Fuel Cell company, and Weichai Power (“Weichai”), one of the leading automobile and equipment manufacturing companies in China, are pleased to announce the finalisation of their long-term strategic collaboration first announced in May 2018. This includes a Joint Venture Agreement with the commitment […]

Parkwalk wins ‘Best Generalist EIS Fund’ in the Investment Week 2018/19 Tax Efficiency Awards

By |December 3rd, 2018|

Parkwalk are delighted to have won ‘Best General EIS Fund’ at Investment Week’s Tax Efficiency Awards 2018 last week, beating last year’s runner’s up prize and matching our win in 2016.

Parkwalk were also highly commended in the ‘Best Exit’ category.

It is always a good validation of our investment strategy to be recognised by industry peers […]

Deal or no deal, should EIS investors be worried about Brexit?

By |December 3rd, 2018|

Given the UK’s Venture Capital Schemes (SEIS, EIS, VCT and SITR) fall under the EU State Aid rules there is the possibility that a ‘hard’ Brexit would allow the Government to loosen restrictions regarding these schemes, but it seems unlikely given the Government’s agenda.

However, under any compromise deal the UK will probably have to […]

25 November 2018

Oxbotica, AXA XL and Nominet to bring autonomous cars to London roads before Christmas

By |November 25th, 2018|

Today the DRIVEN consortium, led by Oxbotica, the autonomous vehicle software provider, announces it will commence trials on London’s roads this month following successful ongoing trials in Oxford. The vehicles will be mapping the streets of Hounslow and are expected to be autonomous by Christmas 2018. During the trials, Nominet and AXA XL will […]

Tom Hopkins joins Parkwalk

By |November 20th, 2018|

Parkwalk are delighted to announce that Tom Hopkins has joined the team as Business Development Director. Tom has worked alongside Parkwalk since early 2015 as one of the co-founders of Kin Capital who provide fundraising services to the Parkwalk EIS Fund and will continue to do so.

Tom has 13 years’ experience across the front, […]

Parkwalk included in Global University Venturing 2018 Powerlist

By |November 12th, 2018|

Global University Venturing has just completed their inaugural Powerlist for 2018 based on their five-year data review of the university spin-out ecosystem earlier this year.

The data from the study showed Parkwalk as the world’s second most active investor in this sector, which can be seen here: Global investors in University spin-outs 2013 – 2017. Parkwalk […]

Duel – University of Bristol Enterprise Fund II investment

By |November 5th, 2018|

We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Duel.

Duel is a centralised hub for managing Ambassador programs and all elements for Customer Advocacy Marketing for brands. It works by taking customers, turning them into advocates, then empowering these advocates to tell a brand’s story and rigorously track the results. […]

Echion – UCEF V investment

By |November 1st, 2018|

We are delighted to announce that the University of Cambridge Enterprise Fund V has invested in a £1.5 million seed funding round (alongside an additional £600k Innovate UK grant) in to Echion Technologies, a spin-out from the University of Cambridge Engineering Department.

Echion is commercialising superfast charging lithium-ion battery cells for electric vehicles, and is seeking […]

20 October 2018

DefiniGEN – Parkwalk closes follow on investment

By |October 20th, 2018|

Parkwalk closes DefiniGen investment.

DefiniGEN, a spin-out from the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital, have created a stem cell technology to provide human cells to the drug discovery sector for use in lead optimisation and toxicity programmes.

The Company’s proprietary production platform OptiDIFF robustly generates human cell types including using hIPSC human […]

Congenica – earns major role in supporting world’s first routine national genomic medicine service

By |October 17th, 2018|

Genomics England names Congenica as its Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service

Cambridge, United Kingdom – 17 October, 2018 – Congenica has been awarded a multi-year contract by Genomics England, to be a provider of Diagnostic Decision Support Services for them to deliver for the world leading NHS Genomic […]

Oxbotica – appoints Fraser Robinson to drive global strategy

By |October 12th, 2018|

Oxbotica, the autonomous software company, today announces the appointment of Fraser Robinson to its board of directors. This follows Oxbotica’s recent completion of a £14 million investment which will support the next stage of its international development.

Robinson comes with a rare and proven track record, most recently leading Uber’s investment negotiations, strategy and partnerships […]

Vitamica – University of Bristol Enterprise Fund II investment

By |October 9th, 2018|

We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Vitamica, a University of Bristol spin-out that aims to exploit a novel approach for determining the susceptibility of bacteria to antibiotics.

Resistance of bacteria to antibiotics is an increasing problem across the world, resulting in poorer healthcare […]

Paragraf – Large-scale production of graphene-based technologies

By |October 6th, 2018|

Paragraf, the Cambridge graphene start-up, has followed its seed investment of £2.9m, announced in May 2018, with the opening of a groundbreaking new facility

The site represents a turning point for graphene-based technologies, enabling Paragraf to drive large-scale development of mass-market, graphene-based electronic devices.

Paragraf’s proprietary production technique overcomes the quality, contamination and reproducibility barriers faced […]

Arkivum – Jersey Heritage contract

By |October 1st, 2018|

Jersey Heritage has chosen Arkivum Perpetua to store and preserve the huge volumes of digital records in its care. Holding the complete public record of States of Jersey, a photo archive of around 1.5 million images and digitised artefacts such as registration cards from the German occupation during World War Two, Jersey Heritage tells […]

27 September 2018

Healthera – UCEF V investment

By |September 27th, 2018|

We are delighted to announce that the University of Cambridge Enterprise Fund V has invested in a £3m Series A financing round into Healthera, a provider of next-generation, pharmacy-integrated personal health management solutions.

Healthera connects patients to a platform of hundreds of pharmacies and NHS GPs, allowing them to order and track prescriptions, access clinical […]